As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

For the uninitiated, Recursion wants to become the go-to provider of AI-based drug discovery and development services for the biopharmaceutical industry. It's also developing a handful of therapies ...